Brazil
Egypt
Europe
Hong Kong
Malaysia
Mexico
Morocco
Philippines
Saudi Arabia
South Africa
Taiwan
Thailand
Tunisia
Turkey
UAE
USA
Vietnam
Global HQ
STORIES
Brand Stories
Biocon Biologics has demonstrated success and established global credibility with several of its molecules being approved and launched in both developed and emerging markets. The company is at an important inflection point as it gains commercial success with its first wave of products and invests in long term sustainability through broadening of its pipeline and commercial presence, further expanding manufacturing scale, and two strategic transactions with Serum Institute Life Sciences and Viatris.
You can read about how Biocon Biologics is evolving as a brand as it focuses, invests, competes and wins in the large and growing opportunity from biosimilars worldwide.
PATIENTS' STORIES
Stories
Biocon Biologics scores 53 in its debut on the S&P Global Corporate Sustainability Assessment for 2024
The S&P Global ESG Score measures a company’s performance on and management of material ESG risks, opportunities…
Bridging the Gap in Diabetes Care by Upskilling Nurses in Ethiopia
Diabetes continues to pose a significant global health challenge, particularly in low- and middle-income countries (LMICs) like Ethiopia…
Biocon Biologics Opens North America Headquarters in New Jersey’s Biopharma Corridor
Biocon Biologics proudly celebrated a significant milestone with the official opening of its new North America headquarters in Bridgewater, New Jersey on Friday, Sept. 13…
Biocon Biologics off to a solid start in Q1 FY25, powered by product sales & market shares
The successful integration of the acquired Biosimilars business dominated the Biocon Biologics growth story last year…
Biocon Biologics breaks billion-dollar barrier, with 58% rise in annual revenue
In the financial year, 2024, Biocon Biologics crossed a significant milestone that set the Company on its way to become a truly global biosimilars leader…
Biosimilars Market Access 101 – Navigating the Canadian Landscape
At Biocon Biologics, we’re passionate about bringing affordable, high-quality biosimilar treatments to patients across the world. In Canada specifically, a critical step in increasing access to biosimilars…
Biocon Biologics Makes Donation to Insulin for Life
Donations of insulin play a crucial role in saving lives, especially for individuals with diabetes who may face challenges in accessing or affording this essential medication…
Biocon Biologics successfully completes integration of acquired biosimilars business in 120 countries
In this phase, over 10 Emerging Markets along with Japan, Australia and New Zealand have transitioned to Biocon Biologics….
Breast Cancer Awareness Month: How to self-examine your breasts in six easy steps
October is marked as Breast Cancer Awareness Month every year to turn the world’s attention to the need for early detection and treatment of the disease…
Diabetes and heart disease have a close connection: Symptoms to be wary of and tips to take care of your heart
We can boast about a braveheart or sigh over a heartbreak. We can light up a room with a hearty laugh, or make someone’s day …
Biocon Biologics’ 4th Biosimilar product bAdalimumab launched in the U.S.
Biocon Biologics launches biosimilar Adalimumab in the US, expands its offering to patients, enters the immunology segment.
Biocon Biologics has a comprehensive plan to integrate Viatris business
Biocon Biologics has put together a comprehensive plan to integrate the acquired Viatris business to ensure continuity of supply and relations with all customers.
Poised for Global Leadership
Leveraging ‘The Power of One’; Enabling Affordable Access to Lifesaving Biosimilars, Worldwide.
Hope. Now within reach.
Aiming to reach a billion patients worldwide with affordable, lifesaving medicines.
EMPLOYEE Stories
Ankur Bhatnagar, Global Head of Research & Development, talks about passionate teamwork, innovation, and ownership drive Biocon Biologics’ mission to transform global healthcare.
Sivanandam K, Our Global Program Head – Program Management, highlights how Program Management has evolved since its inception in 2009.
Deepa Mohan, Our Senior Scientific Manager – R&D, highlights how the Biocon culture is primarily based on innovation.
Anita Rao, Our Project Group Lead – R&D, talks about how her experience in Biocon has enriched her both professionally and technically.
